Pfizer Inc
Change company Symbol lookup
Select an option...
PFE Pfizer Inc
JHI John Hancock Investors Trust
SLGN Silgan Holdings Inc
GBX Greenbrier Companies Inc
GOOG Alphabet Inc
PUCKU Goal Acquisitions Corp
PRGO Perrigo Company PLC
INBS Intelligent Bio Solutions Inc
BLNK Blink Charging Co
PYOIF Promotora y Operadora de Infraestructura SAB de CV
Go

Health Care : Pharmaceuticals | Large Cap Value

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.

Closing Price: $50.91

Day's Change: -0.17 (-0.33%)

Bid: --

Ask: --

B/A Size: --

Day's High: 51.33

Day's Low: 50.48

Volume (Average) Volume: 16,881,642 10-day average volume: 17,852,916: 16,881,642

Yesterday's News, December 01, 2022
10:00 am ET	Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of its Near-Term Launches + High-Value Pipeline Day on Monday, December 12, 2022 from 1:00 p.m. EST to 6:00 p.m. EST, with an approximately 30 minute...(BusinessWire)
8:00 am ET	Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases(Globe Newswire)
1:00 am ET	Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate(Globe Newswire)
November 28, 2022
10:00 am ET	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business; Kevin Sullivan, Global Specialty Care &...(BusinessWire)
November 22, 2022
7:12 am ET	Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)(Globe Newswire)
November 18, 2022
6:45 am ET	Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages(Globe Newswire)
November 16, 2022
6:30 pm ET	Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection NEW YORK and MAINZ, GERMANY, NOVEMBER 16, 2022 -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a Phase 1 study to evaluate the safety, tolerability and immunogenicity of a next generation...(Thomson Reuters ONE)
6:30 pm ET	Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection(Globe Newswire)
November 15, 2022
4:00 pm ET	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE NEW YORK, NY / ACCESSWIRE / November 15, 2022 / Pomerantz LLP is investigating claims on behalf of investors ofPfizer Inc.("Pfizer" or the "Company") (NYSE:PFE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or...(Accesswire)
November 14, 2022
2:35 pm ET	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE Pomerantz LLP is investigating claims on behalf of investors ofPfizer Inc.("Pfizer" or the "Company")(NYSE:PFE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.comor 888-476-6529, ext. 7980. (PR Newswire)
November 11, 2022
10:00 am ET	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Wolfe Research Healthcare Conference on Friday, November...(BusinessWire)
November 10, 2022
9:45 am ET	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union(Globe Newswire)
9:45 am ET	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union NEW YORK and MAINZ, GERMANY, November 10, 2022 -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY(R) Original/Omicron BA.4/BA.5 5/5-ug) has...(Thomson Reuters ONE)
November 09, 2022
3:05 pm ET	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE New York, New York--(Newsfile Corp. - November 9, 2022) - Pomerantz LLP is investigating claims on behalf of investors ofPfizer Inc.("Pfizer" or the "Company") (NYSE: PFE). Such investors are advised to contact Robert S. Willoughby at...(Newsfile)
November 07, 2022
4:31 pm ET	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE(Globe Newswire)
November 05, 2022
1:16 pm ET	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE NEW YORK, NY / ACCESSWIRE / November 5, 2022 / Pomerantz LLP is investigating claims on behalf of investors ofPfizer Inc.("Pfizer" or the "Company") (NYSE: PFE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or...(Accesswire)
November 04, 2022
8:12 am ET	Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine(Globe Newswire)
6:47 am ET	Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated data from a Phase 2/3 clinical trial demonstrating a robust neutralizing immune response one-month after a 30-ug booster dose of the companies' Omicron BA.4/BA.5-adapted...(BusinessWire)
2:50 am ET	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE Pomerantz LLP is investigating claims on behalf of investors of Pfizer Inc. ("Pfizer" or the "Company") (NYSE: PFE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. (PR Newswire)
November 03, 2022
9:10 am ET	Pfizer's Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma Pfizer Inc. (NYSE:PFE) today announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of people with relapsed or refractory multiple...(BusinessWire)
Next >

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and